Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis

Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivit...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis Vol. 13; no. 5; pp. 567 - 577
Main Authors Farrell, Rachel A, Giovannoni, Gavin
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.06.2007
Arnold
Sage Publications Ltd
Subjects
Antibodies - blood
Antibodies - immunology
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Humans
Immunologic Factors - immunology
Immunologic Factors - therapeutic use
Immunomodulators
Interferon-beta - immunology
Interferon-beta - therapeutic use
Medical sciences
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - immunology
Neurology
Pharmacology. Drug treatments
bioassay
Interferon-beta
biological treatment
cytopathic effect assay
MxA bioassay
neutralising antibody
Human
Multiple sclerosis
Nervous system diseases
Bioassay
Inflammatory disease
Persistence
Clinical management
Treatment
Central nervous system disease
Beta interferon
Clinical trial
Strategy
Degenerative disease
Online AccessGet full text

Cover

More Information
Summary:Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS. Multiple Sclerosis 2007; 13: 567-577. http://msj.sagepub.com
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Review-3
ISSN:1352-4585
1477-0970
DOI:10.1177/1352458506073522